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The development of choroidal neovascularization (CNV) is a critical step in the pathogenesis of age-related macular degeneration (AMD), a vision-
threatening disease. In this study, we used a mouse model of AMD to study the protective effects of resveratrol (RSV) supplementation against CNV as well as the
underlying molecular mechanisms. Mice were orally pretreated with RSV daily for 5 days. On the fifth day, the mice underwent laser photocoagulation to induce
CNV. One week after laser treatment, CNV volume was significantly lower in the RSV-treated mice compared with vehicle-treated animals. In addition, RSV
treatment significantly inhibited macrophage infiltration into the retinal pigment epithelium (RPE)-choroid and suppressed the expression of inflammatory and
angiogenic molecules, including vascular endothelial growth factor, monocyte chemotactic protein-1 and intercellular adhesion molecule-1. Importantly, RSV
prevented the CNV-induced decrease in activated AMP-activated protein kinase and increase in activated nuclear factor-κB in the RPE-choroid complex.
The regulatory effects of RSV on these molecules were confirmed in RPE, microvascular endothelial and macrophage cell lines. Inhibition of macrophage
infiltration by RSV was confirmed by in vitro scratch and migration assays. RSV suppressed CNV development, reducing the levels of multiple cytokines secreted
from several cell types and inhibiting macrophage migration. The direct effects of RSV on each cell type were confirmed in vitro. Although further studies are
needed, RSV could potentially be applied in the clinic to prevent CNV development in AMD.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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Choroidal neovascularization (CNV) is the main pathogenesis of
age-related macular degeneration (AMD), the most common cause of
blindness in developed countries [1]. Anti-vascular endothelial
growth factor (VEGF) therapy is used worldwide to suppress CNV
[2]. The positive effects of anti-VEGF drugs are well documented [3,4],
while non-responsive cases are also reported [5]. Moreover, once CNV
has initiated, even when treated, it can breach the barrier consisting
of Bruch’s membrane and retinal pigment epithelium (RPE) cells,
resulting in irreversible changes in retinal neurons. Thus, strategies to
prevent CNV development are now amajor focus of AMD research [6].
A large-scale clinical study, the Age-Related Eye Disease Study 2, has
revealed that micronutrient supplementation with lutein and
zeaxanthin together with multi-vitamins and zinc can suppress the
rate of AMD progression in subjects who were in the lowest quintile
of dietary lutein and zeaxanthin intake [7]. However, there also were
some cases in which less effect was observed in micronutrient⁎ Corresponding author. Laboratory of Retinal Cell Biology, Department
of Ophthalmology, Keio University School of Medicine, 35 Shinanomachi
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approaches for prevention are still anticipated.
The molecular and cellular mechanisms underlying the develop-
ment of CNV have long been studied. The role of macrophages [8,9],
which are a rich source of VEGF and are recruited by the actions
of intercellular adhesion molecule-1 (ICAM-1) and monocyte che-
motactic protein-1 (MCP-1), is well documented, as is the involve-
ment of inflammatory mechanisms such as the renin–angiotensin
system [10,11] and interleukin (IL)-6 receptor signaling [12]. Thus,
inflammation and the associated oxidative stress are logical targets
for preventive therapies [13]. However, practical preventive therapies
have not been fully developed.
Here, we focus on resveratrol (3,5,4-trihydroxystilbene; RSV), an
antioxidant and dietary polyphenol found in red wine and grape skin.
A number of bioactive functions have been attributed to RSV,
including anti-tumorigenic [14], anti-angiogenic [15], anti-atherogenic
[16] and neuroprotective [17,18] functions. RSV can also protect the
cardiovascular system from oxidative stress [19,20]. RSV has been a
focus of research on aging because RSV administration extends the
lifespan of yeast, Caenorhabditis elegans and Drosophila melanogaster by
activating Sir2. Moreover, RSV improves the survival and health ofmice
fedwith a high-fat diet [21]. RSV increases the activity of AMP-activated
protein kinase (AMPK), a fuel-sensing kinase that ameliorates
the pathogenesis of metabolic disorders such as diabetes [22,23].the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Fig. 1. RSV treatment suppressed CNV development. (A) Flat-mounted RPE-choroid
complexes from vehicle- and RSV-treated mice 7 days after laser PC for CNV induction.
CNV tissues were stained with lectin. (B) Graph showing the CNV volume index.
RSV suppressed the CNV volume in the mouse model of AMD. n=16. *Pb.01.
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remodeling of cardiomyocytes in the post-infarction heart through
promoting autophagy [24], inducing vasodilation in the hypertensive
model through increasing NO synthesis [25] and inhibiting cell
proliferation and protein translation in the tumor cells interacting
with estrogen receptor [26]. Thus, RSV-induced AMPK may contribute
to organ health in aged mice stressed by metabolic disorders [21].
Because AMD is an aging-related disease that is often induced
in cases of metabolic syndrome, RSV may represent a promising
candidate for a preventive therapeutic approach. However, neither
the involvement of the AMPK pathway in the mechanisms underlying
CNV development nor the effects of RSV on these mechanisms are
fully understood.
In this study,wepretreatedmicewith oral RSV and then analyzed its
preventive effects on CNV development together with the underlying
molecular mechanisms, focusing on AMPK activation. The direct effects
of RSV on different cell types were also investigated.
2. Methods and materials
2.1. Animals
Six-week-old male C57BL/6J mice (CLEA, Tokyo, Japan) were used. All animal
experiments were conducted in accordance with the Association for Research in Vision
and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision
Research.
2.2. RSV treatment
Animals were pretreated with RSV at a daily dose of 50 mg/kg body weight (Sigma,
St. Louis, MO, USA) or with phosphate-buffered saline (PBS) containing 1% dimethyl
sulfoxide as the vehicle control for 5 days, starting 4 days before and ending on the day
of laser photocoagulation (PC).
2.3. Induction of CNV
Laser-induced CNV is widely used as an animal model of neovascular AMD and
reflects the pathogenesis of the inflammation-related CNV observed in AMD. In thismodel, new vessels from the choroid invade the subretinal space after PC. Laser PC was
performed at 5 spots per eye around the optic disc using a slit-lamp delivery system
(Novus Spectra; Lumenis, Tokyo, Japan) as previously described [9–12,27–30].
2.4. Immunohistochemistry and quantification of laser-induced CNV
One week after laser injury, the mice were sacrificed, and the eyecups were removed
and incubated with 0.5% fluorescein-isothiocyanate-conjugated isolectin B4 (Vector,
Burlingame, CA, USA). CNV was visualized using a scanning laser confocal microscope
(FV1000; Olympus, Tokyo, Japan). The area of CNV-related fluorescence was measured
usingNIH(National Institutes ofHealth) ImageJ software.Horizontal optical sectionsof CNV
were obtained at 1-μmintervals from the surface to the deepest focal plane. The summation
of thewhole fluorescent areawas used as the index for CNVvolume as previously described
[10,11,27–30].
2.5. Immunohistochemistry for infiltrating macrophages
Whole-mount RPE-choroid complexes obtained 3 days after PC were incubated
with a rat polyclonal antibody against macrophage marker F4/80 (Abcam, Raleigh, NC,
USA). Avidin-Alexa 546-tagged secondary antibody (Invitrogen, Carlsbad, CA, USA)
was then applied as previously described [12].
2.6. Real-time reverse-transcription (RT) polymerase chain
reaction (PCR)
Total RNA was isolated from the RPE-choroid complex 1–3 days after PC and
reverse-transcribed. Quantitative PCR analyses for F4/80, VEGF, ICAM-1, MCP-1 and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were performed using an ABI
7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) in
combination with TaqMan probes as previously described [27]. The level of each mRNA
was normalized to that of GAPDH.
2.7. Enzyme-linked immunosorbent assay (ELISA)
Protein extracts were obtained from homogenized RPE-choroid complex 4 h or
3 days after CNV induction by laser PC. In the samples taken 3 days after the PC, VEGF,
MCP-1 and ICAM-1 levels were determined with mouse VEGF, MCP-1 and ICAM-1
ELISA kits (R&D Systems, Minneapolis, MN, USA) as previously described [10]. The
VEGF ELISA kit recognizes all isoforms of VEGF. In the samples obtained 4 h after PC, the
levels of phosphorylated nuclear factor-κB (NF-κB) p65 were analyzed with a mouse
phosphorylated NF-κB p65 ELISA kit (Cell Signaling Technology, Beverly, MA, USA). For
the ELISA assays performed on the in vitro samples, the details of the sampling are
described below.
2.8. Immunoblot analyses
Protein extracts were obtained from homogenized RPE-choroid complexes
prepared 4 h after PC. Immunoblot analyses were performed as described previously
[12]. A rabbit polyclonal antibody against phosphorylated AMPK (Cell Signaling
Technology) and a mouse monoclonal antibody against α-tubulin (1:1000; T9026,
Sigma-Aldrich, Tokyo, Japan) were used, and the protein level of pAMPK was
normalized to that of α-tubulin.
2.9. Cell lines
Three cell lines were prepared: RPE cells (the human cell line ARPE-19),
microvascular endothelial cells (the murine cell line b-End3) and macrophages (the
murine cell line RAW264.7). The cells were treated with RSV (10 μM) or vehicle in
serum-free DMEM/F12 (Sigma) for the ARPE-19 cells or in serum-free DMEM for the b-
End3 and RAW264.7 cells. RSV was applied from 1.5 h before and through the course of
stimulation with tumor necrosis factor-α (TNF-α; Sigma; 10 ng/ml for ARPE-19 and b-
End3 cells; 20 ng/ml for RAW264.7 cells). To inhibit AMPK activation, the cells were
pretreated with an AMPK inhibitor, compound C (10 μM; Calbiochem, La Jolla, CA, USA),
under TNF-α stimulation. After a 20-min incubation, the cell lysates were subjected to
ELISA for phosphorylated NF-κB p65. After a 6-h incubation, the cell lysates or culture
supernatants were subjected to ELISA for ICAM-1, MCP-1 or VEGF.
2.10. Scratch assay
RAW264.7 cells were grown to confluence on 24-well tissue dishes, and a single
scratch was made using a sterile 1000-μl pipette tip. The cells were washed with PBS and
treated with RSV (10 μM) with or without compound C (10 μM) in serum-free DMEM
containingMCP-1 (50 ng/ml; R&D Systems). Photographs were taken after 24 h, and the
cell-covered area was measured by NIH Image.
2.11. Transmigration assay
The effect of RSV onmacrophagemigration was assessed in a 96-well microchamber
(Trevigen Inc., Gaithersburg,MD, USA). RAW264.7macrophageswere added to the upper
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wells were separated from the lower chamber by an 8-μm-pore collagen-coated
polyethylene terephthalate membrane. The lower chamber contained MCP-1 (200 ng/
ml; R&DSystems) in serum-freeDMEM.After 24 h, the transmigrated cellswere analyzed
by a calcein acetomethylester system (Trevigen Inc.).
2.12. Statistical analyses
All results are expressed as the mean±S.D. The values were subjected to statistical
analyses (one-way analysis of variance with Tukey’s post hoc test). The differences
were considered statistically significant at Pb.05.
3. Results
3.1. RSV treatment suppressed CNV development
We first calculated the CNV volumes 7 days after induction in mice
pretreatedwith control vehicle or RSV. TheCNVvolumewas significantly
suppressed by RSV treatment (Pb.01, Fig. 1).
3.2. RSV treatment inhibited macrophage infiltration
To examine how RSV suppresses CNV development, we analyzed
macrophage infiltration in the RPE-choroid complex 3 days after CNV
induction, when the infiltration is at its peak [31], by immunohisto-
chemistry for the macrophage marker F4/80 (Fig. 2A). The RSV-
treated mice showed less immunoreactivity for F4/80 in the RPE-
choroid complex compared with vehicle-treated animals. We further
measured the mRNA level of F4/80 in the RPE-choroid by quantitative
RT PCR (Fig. 2B) and found that there was a trend of suppression at
day 1 and a significant suppression at day 2 in the RSV-treated miceFig. 2. RSV treatment inhibited macrophage infiltration. (A) The presence of
macrophages in the RPE-choroid complexes of mice treated with vehicle or RSV was
evaluated by immunohistochemistry for F4/80 3 days after CNV induction. (B) RSV
suppressed the mRNA levels of F4/80 in the RPE-choroid at days 2 and 3, while it
tended to suppress at day 1. n=8–10. *Pb.01, †Pb.05.(Pb.01, Fig. 2B). The suppressive effect was also observed at day 3
(Pb.05, Fig. 2B). Taken together, the results suggested that the
macrophage infiltration during the process of CNV development was
suppressed by RSV.
3.3. RSV treatment reduced the levels of inflammatory and
angiogenic molecules
We next measured the protein levels of VEGF, ICAM-1 and MCP-1
in the RPE-choroid complex 3 days after CNV induction by ELISA. The
protein levels of all of these inflammatory and angiogenic molecules
[32,33] were higher in the RPE-choroid complexes of CNV-induced
mice compared with age-matched normal controls. These increases
were significantly suppressed by RSV treatment (Pb.01 for VEGF and
Pb.05 for MCP-1 and ICAM-1, Fig. 3A–C).
3.4. RSV treatment activated AMPK and suppressed NF-κB in
the RPE-choroid complex
Because AMPK activation is a known effect of RSV [34], we
measured the levels of phosphorylated (activated) AMPK by
immunoblot analysis. We found that the levels of activated AMPK
were decreased in the RPE-choroid 4 h after CNV induction (P=.005).
This reduction was prevented by RSV pretreatment (P=.02, Fig. 4A).
Knowing that activated AMPK can suppress NF-κB [35], a common
upstream modulator of inflammatory and angiogenic molecules, we
next measured levels of activated NF-κB p65 in the RPE-choroid by
ELISA. The levels of phosphorylated (activated) NF-κB p65 were
increased 4 h after CNV induction (Fig. 4B). RSV pretreatment
significantly suppressed this change (P=.003), indicating that RSV
may have suppressed NF-κB activation by increasing the levels of
activated AMPK.
3.5. RSV inhibited NF-κB and inflammatory and angiogenic
molecules in vitro
To analyze the direct effects of RSV on various cell types that may
be involved in the pathogenesis of CNV, we prepared 3 cell lines,
ARPE-19 cells (RPE cells), b-End3 cells (microvascular endothelial
cells) and RAW264.7 cells (macrophages) (Fig. 5). ELISA analyses
revealed that the protein levels of phosphorylated (activated) NF-κB
were increased by TNF-α stimulation in all 3 cell lines. However,
importantly, RSV treatment significantly decreased the levels of
activated NF-κB p65 in all 3 cell lines (Pb.05, Fig. 5A, D and G).
Moreover, these effects were attenuated by an AMPK inhibitor,
compound C (Pb.05, Fig. 5A, D and G), indicating that RSV decreased
NF-κB activation via AMPK activation in these 3 cell lines.
Next, the protein levels of inflammatory and angiogenic molecules
were measured by ELISA. In the ARPE-19 RPE cell line, TNF-α induced
VEGF (Fig. 5B) and MCP-1 (Fig. 5C). Both increases were significantly
suppressed by RSV treatment (Pb.001 for VEGF; Pb.05 for MCP-1). In the
b-End3 microvascular endothelial cell line, RSV application significantly
reversed the TNF-α-induced increases in ICAM-1 (Pb.001, Fig. 5E) and
MCP-1 protein levels (Pb.001, Fig. 5F). Similarly, in RAW264.7 macro-
phages, RSV treatment significantly (Pb.01) blocked the TNF-α-induced
increase in VEGF protein levels (Fig. 5H). Notably, all of these inhibitory
effects of RSV were significantly attenuated by treatment with the AMPK
inhibitor compound C (Pb.05 for all, Fig. 5B, C, E, F and H), indicating that
RSV’s effects on inflammatory and angiogenic molecules were mediated
by AMPK activation and the subsequent decrease in activated NF-κB.
3.6. RSV suppressed macrophage migration in vitro
To analyze the direct effects of RSV on macrophage infiltration,
scratch and transmigration assays were performed. RSV significantly
Fig. 3. RSV treatment reduced the levels of inflammatory and angiogenic molecules.Protein levels of VEGF (A), ICAM-1 (B) and MCP-1 (C) were increased 3 days after CNV induction.
RSV pretreatment significantly suppressed these increases. n=8. **Pb.001, *Pb.01, †Pb.05.
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(Fig. 6C) of RAW264.7 macrophages. However, these effects were
significantly suppressed by treatment with the AMPK inhibitor
compound C. Thus, RSV suppressed macrophage migration through
activation of AMPK.
4. Discussion
In the present work, we show that RSV has anti-pathogenic
effects on CNV development (Fig. 1), reducing macrophage infiltra-
tion (Fig. 2) and inflammatory and angiogenic cytokines in the RPE-
choroid complex (Fig. 3). RSVsuppressed thedecrease in activatedAMPK
and the increase in NF-κB in the RPE-choroid after laser PC for CNV
induction (Fig. 4). In vitro assays confirmed that RSV suppressed NF-κB
activation; reduced the levels of inflammatory and angiogenicmolecules
in RPE cells, vascular endothelial cells and macrophages; and inhibited
the migration of macrophages via AMPK activation (Figs. 5 and 6). RSV
acted directly on the cells. These data suggest that, under pathological
conditions, RSV has multiple effects on 3 different types of cells in the
RPE-choroid, i.e., RPE cells, vascular endothelial cells and macrophages,
which may coordinately contribute to CNV development (Fig. 7).
The role of VEGF in CNV progression is well accepted [36,37].
Current standard therapy targets VEGF to suppress the progression of
CNV that has already developed. However, a previous study that usedFig. 4. RSV treatment activated AMPK and suppressed NF-κB in the RPE-choroid complex.Pho
p65 was induced (B) in the RPE-choroid 4 h after CNV induction. These effects were blockedpharmacological macrophage depletion with liposomal clodronate
demonstrated the contribution of macrophages to CNV development:
phagocytosis of liposomal clodronate by macrophages rapidly
induced apoptosis without proinflammatory cytokine secretion and
resulted in CNV suppression [31]. Macrophages can also be anti-
angiogenic depending on their condition; the intensity of the CNV
development may be relied on a balance between M1 and M2
macrophages [38–40]. The macrophages that we observed during
CNV development might have included both types. Whether RSV can
regulate the balance may be an interesting research topic in the
future. The importance of MCP-1, which recruits macrophages, was
demonstrated using MCP-1 knockout mice [8,41]. Another group
showed that atorvastatin, an HMG CoA reductase inhibitor that is
widely used in patients with atherosclerotic disease and hyperlipid-
emia, reduces macrophage infiltration and CNV size in a dose-
dependent manner, in accord with decreased MCP-1 expression [42].
Moreover, ICAM-1, anadhesion factor for leukocytes that is expressed in
vascular endothelial cells and precedes CNV development [10,27,43],
alsoplays a role in CNVdevelopment: ICAM-1-deficientmice developed
smaller size of CNVs in the laser-induced CNV model [9].
Given these findings, as well as the fact that macrophages are
found at the damaged area of Bruch’s membrane where CNV invasion
can be facilitated [44,45], macrophage targeting therapy might be
effective at preventing AMD progression if applied during the verysphorylated (activated) AMPK was reduced (A), and phosphorylated (activated) NF-κB
by RSV. *Pb.01, †Pb.05.
Fig. 5. RSV inhibited NF-κB and inflammatory and angiogenic molecules in vitro. ARPE-19 cells (A–C), b-End3 microvascular endothelial cells (D–F) and RAW264.7 macrophages
(G and H) were stimulated with TNF-α. RSV significantly suppressed the phosphorylation (activation) of NF-κB by TNF-α (A, D and G) and the subsequent induction of VEGF (B and H),
MCP-1 (C and F) and ICAM-1 (E). All of the effects of RSV were attenuated by an AMPK inhibitor, compound C. n=8. **Pb.001, *Pb.01, †Pb.05.
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inhibitory effects of RSV on macrophage infiltration and cytokine
expressionwill provide a basic therapeutic rationale for the use of RSV
in AMD prevention. Both mRNAs of MCP-1 and ICAM-1 were already
suppressed by RSV 1 day after CNV induction (Supplementary Fig. 1)
and mRNA of F4/80 was also suppressed at day 2, while a significant
reduction of VEGF mRNA was observed at day 3 in the whole RPE-
choroid. These results suggested that the macrophage inducing
activity that subsequently promotes CNV development can be
suppressed by RSV from the early phase. Moreover, RSV also acted
on RPE and vascular endothelial cells and reduced the production of
cytokines related to vascular proliferation and/or macrophageinfiltration (VEGF, ICAM-1 and MCP-1), suggesting that RSV
might offer a multistep targeting therapy. The facts that RSV can
suppress IL-6 [46,47] and IL-1b [48,49] both in vivo and in vitro
further suggest the RSV’s multistep targeting in terms of suppressing
multiple kinds of inflammatory cytokines. Moreover, RSV could also
improve the systemic condition improving insulin resistance [50] and
hypertension [25] that could reduce the risk of AMD in human [51],
although further studies are required.
We also found that the effects of RSV observed in this study were
mediated by AMPK activation. In vitro data showed that the actions of
RSV on RPE cells, vascular endothelial cells and macrophages were
all mediated by AMPK activation. AMPK, in turn, suppressed NF-κB,
Fig. 6. RSV suppressed macrophage migration in vitro.Scratch (A and B) and transmigration assays (C). The effects of RSV were attenuated by an AMPK inhibitor, compound C. n=8.
*Pb.01, †Pb.05.
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therefore, the series of events was theoretically consistent. However,
theremaywell be other pathways besides NF-κB that act downstream
of AMPK.
A previous study reported an inhibitory effect of RSV on CNV
development, specifically related to the proliferation of vascular
endothelial cells [52]. RSV-induced activation of AMPK results in the
phosphorylation of a serine residue of eukaryotic elongation factor 2 (eEF2)
kinase, which inactivates eEF2 through threonine phosphorylation. It wasFig. 7. A model for the preventive effects of RSV on CNV.RSV treatment significantly
suppresses CNV development by preserving AMPK activation, which inhibits
macrophage recruitment as well as the induction of inflammatory processes, including
NF-κB activation and the subsequent up-regulation of inflammatory and angiogenic
molecules such as ICAM-1, MCP-1 and VEGF in multiple cell types. PC, laser PC for CNV
induction; Vascular EC, vascular endothelial cells.previously proposed that, because eEF2 promotes protein synthesis,
its inactivation might inhibit cell division. Another group reported
RSV’s inhibitory effect on CNV and RSV’s in vitro effect on cell survival;
RSV inhibited acrolein-induced ARPE-19 cell death by increasing the
mitochondria biogenesis [53].
Whereas the previous studies showed a specific effect of RSV on
vascular endothelial cells, or suggested theeffect onRPE, thepresentwork
expands on this finding to show that RSV inhibits CNV development
through multiple additional mechanisms affecting macrophages as well
as endothelial cells and RPE.
An anti-inflammatory function of AMPK has also been document-
ed in other tissues and organs. In experimental autoimmune
encephalomyelitis [54], acute and chronic colitis [55] and lipopoly-
saccharide-induced lung injury in mice [56], the induction of
inflammatory proteins, such as IL-6 and TNF-α, is attenuated by the
artificial activation of AMPK by 5-aminoimidazole-4-carboxamide-1-
beta-4-ribofuranoside. In LPS-induced inflammation in rat skeletal
muscle and adipose tissue, AMPK inhibits inducible nitric-oxide
synthase (iNOS), a proinflammatory mediator of endotoxic shock and
chronic inflammatory states, including obesity-linked diabetes [57];
this action occurs through post-transcriptional regulation of the iNOS
protein. Therefore, AMPK inhibits inflammation through multiple
pathways in several different cell types.
Most current therapies for AMD target VEGF. However, the
continuous inhibition of VEGF to suppress CNV may be harmful for
the surrounding tissues, as VEGF has important physiological roles in
maintaining the choroidal vessels that feed the retina [58] and in
supporting the survival of retinal neural cells under pathogenic
conditions [59,60]. Moreover, once CNV has developed, the neural
retina may be permanently damaged. Thus, a preventive therapy is
required. The current study explored the molecular basis of CNV
development. Our findings indicate that RSV exerts a therapeutic
effect by preserving the level of activated AMPK under pathogenic
conditions. Notably, RSV suppressed CNV development by targeting
not only VEGF but also multiple other cytokines secreted from several
cell types, as well as by inhibiting macrophage migration. Although
1224 N. Nagai et al. / Journal of Nutritional Biochemistry 25 (2014) 1218–1225further studies are needed, RSV could be potentially applied clinically
to prevent CNV development in AMD.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jnutbio.2014.05.015.
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